A trio of hepatitis C regimens has been linked to cases of worsening function or failure of the liver.
Those affected are some of those with advanced liver disease taking AbbVie’s (NYSE: ABBV) Mavyret (glecaprevir/pibrentasvir), Merck & Co’s (NYSE: MRK) Zepatier (elbasvir/grazoprevir) or Gilead Sciences’ (Nasdaq: GILD) Vosevi (sofosbuvir/velpatasvir/voxilaprevir).
The US Food and Drug Administration (FDA) has put out a MedWatch safety alert warning of these rare occurrences. The agency identified 63 cases of worsening liver function, or decompensation, among hepatitis C patients taking these regimens.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze